Paper42936601PubMed
CAR-T-cell therapy for autoimmune neurologic diseases.
Zhao Y and 6 others. Front Immunol, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. CAR-T-cell therapy for autoimmune neurologic diseases. Papers, record 42936601. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42936601
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CAR-T-cell therapy for autoimmune neurologic diseases.
- Journal
- Front Immunol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-28
Source PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Autoimmune Diseases of the Nervous System | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| T-Lymphocytes | Major topic |
| Humans | |
| Animals | |
| B-Lymphocytes |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23290630 | Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. | Lancet Neurol | 2013 | https://conductscience.org/library/papers/23290630 | PubMed |
| 2 | 39874224 | CD19-CAR T-cell therapy induces deep tissue depletion of B cells. | Ann Rheum Dis | 2025 | https://conductscience.org/library/papers/39874224 | PubMed |
| 3 | 41101309 | Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. | Cell | 2025 | https://conductscience.org/library/papers/41101309 | PubMed |
| 4 | 29972754 | Chimeric Antigen Receptor Therapy. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29972754 | PubMed |
| 5 | 33324003 | B cell depletion therapies in autoimmune disease: advances and mechanistic insights. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33324003 | PubMed |
| 6 | 40706586 | Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis. | Med | 2025 | https://conductscience.org/library/papers/40706586 | PubMed |
| 7 | 36070711 | Neuromyelitis Optica Spectrum Disorder. | N Engl J Med | 2022 | https://conductscience.org/library/papers/36070711 | PubMed |
| 8 | 26906964 | A clinical approach to diagnosis of autoimmune encephalitis. | Lancet Neurol | 2016 | https://conductscience.org/library/papers/26906964 | PubMed |
| 9 | 30592986 | ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. | Biol Blood Marrow Transplant | 2019 | https://conductscience.org/library/papers/30592986 | PubMed |
| 10 | 36198831 | Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. | Nat Rev Rheumatol | 2022 | https://conductscience.org/library/papers/36198831 | PubMed |
| 11 | 31050279 | Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31050279 | PubMed |
| 12 | 38697115 | Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. | Neuron | 2024 | https://conductscience.org/library/papers/38697115 | PubMed |
| 13 | 36109639 | Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. | Nat Med | 2022 | https://conductscience.org/library/papers/36109639 | PubMed |
| 14 | 39106426 | CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year. | Neurol Neuroimmunol Neuroinflamm | 2024 | https://conductscience.org/library/papers/39106426 | PubMed |
| 15 | 36706773 | Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. | Lancet Neurol | 2023 | https://conductscience.org/library/papers/36706773 | PubMed |
| 16 | 41514038 | BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. | Nat Med | 2026 | https://conductscience.org/library/papers/41514038 | PubMed |
| 17 | 35025605 | Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. | Science | 2022 | https://conductscience.org/library/papers/35025605 | PubMed |
| 18 | 37353278 | Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. | Lancet Neurol | 2023 | https://conductscience.org/library/papers/37353278 | PubMed |
| 19 | 37977704 | Anti-CD19 CAR T cells for refractory myasthenia gravis. | Lancet Neurol | 2023 | https://conductscience.org/library/papers/37977704 | PubMed |
| 20 | 21298406 | Anti-NMDA-Receptor Encephalitis and Other Synaptic Autoimmune Disorders. | Curr Treat Options Neurol | 2011 | https://conductscience.org/library/papers/21298406 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42936601
GET https://conductscience.org/api/papers/v1/42936601/references?page=2